ALRN-6924, an MDM2/4 antagonist currently in clinical trials, is administered intravenously [32], but clinical use of subcutaneous injections for anti-cancer agents like Trastuzumab and Methotrexate [33] demonstrates the clinical applicability of this route. Here, MDM2 is linked to cancer.